242 related articles for article (PubMed ID: 17691918)
21. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
22. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.
Huang Z; Ung T
Curr Drug Metab; 2013 Feb; 14(2):226-38. PubMed ID: 23092311
[TBL] [Abstract][Full Text] [Related]
23. Modulation of expression/function of intestinal P-glycoprotein under disease states.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
[No Abstract] [Full Text] [Related]
24. Regulation of biliary drug efflux pump expression by hormones and xenobiotics.
Fardel O; Payen L; Courtois A; Vernhet L; Lecureur V
Toxicology; 2001 Oct; 167(1):37-46. PubMed ID: 11557128
[TBL] [Abstract][Full Text] [Related]
25. Structural and functional aspects of P-glycoprotein and its inhibitors.
Mollazadeh S; Sahebkar A; Hadizadeh F; Behravan J; Arabzadeh S
Life Sci; 2018 Dec; 214():118-123. PubMed ID: 30449449
[TBL] [Abstract][Full Text] [Related]
26. LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.
Zhitomirsky B; Farber H; Assaraf YG
J Cell Mol Med; 2018 Apr; 22(4):2131-2141. PubMed ID: 29377455
[TBL] [Abstract][Full Text] [Related]
27. Three decades of P-gp inhibitors: skimming through several generations and scaffolds.
Palmeira A; Sousa E; Vasconcelos MH; Pinto MM
Curr Med Chem; 2012; 19(13):1946-2025. PubMed ID: 22257057
[TBL] [Abstract][Full Text] [Related]
28. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
[TBL] [Abstract][Full Text] [Related]
29. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
30. The structure and functions of P-glycoprotein.
Li Y; Yuan H; Yang K; Xu W; Tang W; Li X
Curr Med Chem; 2010; 17(8):786-800. PubMed ID: 20088754
[TBL] [Abstract][Full Text] [Related]
31. Biophysical aspects of P-glycoprotein-mediated multidrug resistance.
Wadkins RM; Roepe PD
Int Rev Cytol; 1997; 171():121-65. PubMed ID: 9066127
[TBL] [Abstract][Full Text] [Related]
32. How can we best use structural information on P-glycoprotein to design inhibitors?
McDevitt CA; Callaghan R
Pharmacol Ther; 2007 Feb; 113(2):429-41. PubMed ID: 17208306
[TBL] [Abstract][Full Text] [Related]
33. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
34. P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update.
Yang X; Liu K
Curr Drug Metab; 2016; 17(8):806-826. PubMed ID: 27364832
[TBL] [Abstract][Full Text] [Related]
35. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
Pharm Res; 1998 Jul; 15(7):1001-6. PubMed ID: 9688051
[TBL] [Abstract][Full Text] [Related]
36. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
37. Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy.
Saneja A; Dubey RD; Alam N; Khare V; Gupta PN
Curr Cancer Drug Targets; 2014; 14(5):419-33. PubMed ID: 24720364
[TBL] [Abstract][Full Text] [Related]
38. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of p-glycoprotein--lead identification and optimisation.
Pleban K; Ecker GF
Mini Rev Med Chem; 2005 Feb; 5(2):153-63. PubMed ID: 15720285
[TBL] [Abstract][Full Text] [Related]
40. New insight into p-glycoprotein as a drug target.
Breier A; Gibalova L; Seres M; Barancik M; Sulova Z
Anticancer Agents Med Chem; 2013 Jan; 13(1):159-70. PubMed ID: 22931413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
